cystic fibrosis therapeutics in major developed markets to 2019 - cftr modulators initiate drive...
DESCRIPTION
Market Research Reports, Inc. has announced the addition of “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth” research report to their offering. More information visit- http://mrr.cm/ZkFTRANSCRIPT
www.MarketResearchReports.com
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators
Initiate Drive towards Personalized
Treatment and Market Growth
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com
Introduction to Report
Launch Date: February 7, 2014
Number of Pages: 76
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 3,500
Price For Site License: USD 7,000
Price For Global User License: USD 10,500
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com
About the Report
The report provide value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate (CAGR) of 30.4%.
Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period.
www.MarketResearchReports.com
Research Findings
The Cystic Fibrosis (CF) market will grow rapidly over the forecast period (2012-2019) at a Compound Annual Growth Rate (CAGR) of 30.6%. The sharp rise in market value is due to powerful new drugs entering the market, in particular the novel disease-modifying Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators.
Although very expensive, CFTR modulators are the first to act directly on the defective CFTR protein, which is the root cause of CF. As a result they represent the closest therapy to a cure currently available for CF patients. One CFTR modulator, Kalydeco (ivacaftor), is currently on the market, although it can only treat 5% of people with a specific mutation (O’Reilly and Elphick, 2013).
www.MarketResearchReports.com
Research Findings Continues…
Despite the low treatment population, it has already become one of the top-grossing drugs since its launch in 2012. A second CFTR modulator, lumacaftor, is expected to be launched in 2015. This drug is used in combination with Kalydeco and it is expected to be usable in over 80% of the CF population, which, combined with its large cost and uptake is expected to be the primary driver in the CF market surge.
The prevalence of CF will rise slowly over the forecast period by an estimated 10,000 cases. The primary cause of this is the increasing life expectancy of CF patients, which has rapidly grown over the past three decades as the understanding of the causes of CF has developed (Davies et al., 2007).
www.MarketResearchReports.com
Reasons To Buy
The report enables clients to develop a strong understanding of CF as a disease and a market. The current therapeutic needs and future market trends contained in this report will highlight market opportunities and the scope of competition between CF therapeutics. Primarily, the report will allow clients to
Understand the CF pipeline and the clinical needs it is addressing. In particular, the importance and benefits of CFTR modulators are highlighted and compared with symptomatic treatments.
Develop their knowledge of key products that may enter the market before 2019. Detailed profiles of these products are provided, with a focus on their clinical trial performance, as well as how they can be incorporated into the CF treatment plan and what competition they face.
www.MarketResearchReports.com
Reasons To Buy Continues
Assess the risk associated with CF clinical trials compared with both industry and therapy area averages. In addition, in order to understand the trends in both trial size and duration according to mechanism of action or molecule type.
Identify patterns of growth in the CF market over the forecast period and understand the underlying causes, as well as observing the contributions made by each major market to this growth.
www.MarketResearchReports.com
Report Coverage
1. Table of Contents2. Introduction3. Marketed Products4. Developmental Pipeline5. Market Forecast to 20196. Strategic Consolidations7. Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com
Custom Research: Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.
For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center
www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and purchase this publication:
http://www.marketresearchreports.com/gbi-research/cystic-fibrosis-therapeutics-major-developed-markets-2019-cftr-modulators-initiate
About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.
Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)